Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223

Roche

Status: Completed

Conditions: Breast Cancer

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02383576

MO29587

Details and patient eligibility

About

This study aims to understand better the effective results from the IMELDA MO22223 P-trial (NCT00929240) and see if the anti-cancer therapies given during its follow-up time after study treatments were terminated possibly had an effect on efficacy results.

Enrollment: 185 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Having been randomized in the IMELDA MO22223 P-trial

Exclusion criteria

Not having been randomized in the IMELDA MO22223 P-trial

Trial design

185 participants in 2 patient groups

Bevacizumab

Description:

Participants who received bevacizumab in IMELDA (MO22223) P-trial and were in maintenance phase were observed.

Treatment:

Other: No Intervention

Bevacizumab and Capecitabine

Description:

Participants who received bevacizumab and capecitabine in IMELDA (MO22223) P-trial and were in maintenance phase were observed.

Treatment:

Other: No Intervention